A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects

Trial Profile

A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs DS 1040 (Primary) ; Clopidogrel
  • Indications Stroke
  • Focus Adverse reactions
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 18 Mar 2017 Results evaluating safety and pharmacokinetics of DS-1040 in combination with Clopidogrel, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 16 Jun 2016 Status changed from recruiting to completed.
    • 17 Feb 2016 Planned end date changed from 1 Dec 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top